长春西汀治疗慢性脑供血不足的疗效及不良反应发生率分析

Analysis of the Curative Effect of Vinpocetine in the Treatment of Chronic Cerebral Insufficiency and the Incidence of Adverse Reactions

目的分析长春西汀治疗慢性脑供血不足的疗效及不良反应发生率。方法在该院2019年3月—2020年1月接受治疗的慢性脑供血不足患者中便利抽选88例作为观察对象,用数字随机分组的方式将患者分为两组,对照组患者均给予丹参注射液治疗,观察组患者接受长春西汀治疗。比较两组患者的临床疗效、不良反应发生情况,分析两组患者左、右侧椎动脉(LVA、RVA)、基底动脉(BA)血流速度改善情况。结果观察组患者的临床总好转率(95.45%)高于对照组(79.55%),差异有统计学意义(χ^(2)=5.091,P<0.05);观察组和对照组患者的不良反应发生率分别为18.18%、11.36%,差异无统计学意义(P>0.05);治疗前,两组患者的LVA、RVA和BA相比较,差异无统计学意义(P>0.05),治疗后观察组患者的LVA(31.98±4.61)cm/s、RVA(33.96±4.08)cm/s、BA(35.93±4.08)cm/s均明显高于对照组(29.64±3.48)、(29.43±3.45)、(28.39±3.46)cm/s,差异有统计学意义(t=2.687、5.624、9.349,P<0.05)。结论长春西汀治疗慢性脑供血不足的临床疗效可观,且安全性较高,具有进一步推广应用于今后临床中的价值。

Objective To analyze the curative effect and the incidence of adverse reactions of vinpocetine in the treatment of chronic cerebral insufficiency.Methods In the hospital from March 2019 to January 2020,88 patients with chronic cerebral insufficiency were conveniently selected as observation objects,and the patients were divided into two groups by number randomization.The patients in the control group were treated with Danshen injection,and the patients in the observation group were treated with Vinpocetine.The clinical efficacy and adverse reactions of the two groups of patients were compared,and the improvement of the blood flow velocity of the left and right vertebral artery(LVA,RVA)and basilar artery(BA)of the two groups of patients was analyzed.Results The total clinical improvement rate of patients in the observation group(95.45%)was higher than that of the control group(79.55%),and the difference was statistically significant(χ^(2)=5.091,P<0.05);the incidence of adverse reactions in the observation group and the control group were 18.18%,11.36%,the difference was not statistically significant(P>0.05).Before treatment,there was no statistically significant difference in LVA,RVA and BA between the two groups of patients(P>0.05).After treatment,the LVA(31.98±4.61)cm/s,RVA(33.96±4.08)cm/s,BA(35.93±4.08)cm/s of the observation group were significantly higher than those of the control group(29.64±3.48)cm/s,(29.43±3.45)cm/s,(28.39±3.46)cm/s,the difference was statistically significant(t=2.687,5.624,9.349,P<0.05).Conclusion Vinpocetine has considerable clinical efficacy and high safety in the treatment of chronic cerebral insufficiency.It has the value of further promotion and application in clinical practice in the future.